Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a neutral rating to a buy rating in a research note issued to investors on Monday morning, Marketbeat.com reports. They currently have $47.00 target price on the specialty pharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald reaffirmed a buy rating and issued a $49.00 price target on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 19th. Cowen reaffirmed a buy rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Jefferies Group reaffirmed a buy rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 20th. FBR & Co assumed coverage on Supernus Pharmaceuticals in a research report on Thursday, October 19th. They issued a buy rating and a $53.00 price target for the company. Finally, BidaskClub raised Supernus Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 17th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $49.60.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at $37.55 on Monday. Supernus Pharmaceuticals has a fifty-two week low of $21.60 and a fifty-two week high of $50.04. The company has a market cap of $1,880.00, a price-to-earnings ratio of 35.00, a PEG ratio of 1.57 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. equities analysts forecast that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of SUPN. BlackRock Inc. raised its position in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after buying an additional 31,331 shares during the last quarter. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after buying an additional 984,200 shares during the last quarter. State Street Corp raised its position in Supernus Pharmaceuticals by 3.1% in the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after buying an additional 42,165 shares during the last quarter. Rice Hall James & Associates LLC raised its position in Supernus Pharmaceuticals by 24.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after buying an additional 267,971 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Supernus Pharmaceuticals by 10.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after buying an additional 122,042 shares during the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/12/08/supernus-pharmaceuticals-supn-lifted-to-buy-at-janney-montgomery-scott.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.